BP11136 PLGA 65:35, Carboxyl-Terminated, IV: 0.65–0.8 dl/g, Mw: 88–117 kDa

PLGA 65:35, Carboxyl-Terminated, IV: 0.65–0.8 dl/g, Mw: 88–117 kDa Description

PLGA 65:35, Carboxyl-Terminated, IV: 0.65–0.8 dl/g, Mw: 88–117 kDa is a copolymer of polylactic acid and polyglycolic acid designed with carboxyl end groups to facilitate predictable hydrolytic degradation. The specified intrinsic viscosity and molecular weight range indicate controlled polymer chain lengths, which directly influence the material's degradation kinetics and processability. Presented in powder form, the polymer supports uniform mixing and scalable processing for biomedical applications.

PLGA 65:35, Carboxyl-Terminated, IV: 0.65–0.8 dl/g, Mw: 88–117 kDa Applications

1.         Healthcare Applications
- Use as a matrix in implantable drug delivery systems to achieve sustained release profiles by leveraging its controlled degradation rate.
- Applied as scaffolding in tissue engineering to promote cell proliferation by harnessing its biocompatible and predictable resorption properties.

2.         Research and Development Applications
- Used as a carrier in experimental formulations to evaluate degradation kinetics by leveraging its defined molecular characteristics.
- Frequently used for in vitro studies to simulate in vivo degradation behaviour, supporting data-driven adjustments in polymer design.

PLGA 65:35, Carboxyl-Terminated, IV: 0.65–0.8 dl/g, Mw: 88–117 kDa Packaging

The powder is packed in moisture barrier pouches and sealed in an inert atmosphere container to prevent contamination and premature degradation. Storage should occur in a cool, dry environment, away from direct light. Anti-static measures are implemented to reduce particulate accumulation. Custom packaging options including vacuum sealing or secondary packaging with desiccant are available upon request.

Additional Information

Understanding the degradation behaviour of PLGA-based polymers is vital for designing biomedical devices. The hydrolytic breakdown of these polymers enables them to safely resorb in biological environments without the need for an additional removal procedure. Researchers benefit from the ability to modulate degradation rates through molecular weight and end-group modifications.

PLGA materials have broad implications in regenerative medicine and drug delivery. Their predictable performance under physiologic conditions supports experimental verification, contributing to advancements in controlled release systems and tissue engineering scaffolds. Educational research continues to refine these materials for improved clinical outcomes.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.